• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Intermittent vagal nerve block ineffective for weight loss in obesity

byMilana Bogorodskaya, MDandPriyanka Vedak
September 2, 2014
in Chronic Disease, Gastroenterology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In patients with morbid obesity, intermittent intra-abdominal vagal nerve blockade did not induce significant body weight loss (>20%) when compared to a placebo device.

2. While the safety profile of the device itself was low, adverse events associated with abdominal surgery and anesthesia persist.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: The vagus nerve interacts with the gastrointestinal track to influence dietary intake through multiple mechanisms. This study sought to provide an alternative to current bariatric surgeries for the treatment of morbid obesity. Results showed that while intermittent intra-abdominal vagal nerve blockade resulted in more weight loss than the placebo device, this weight loss did not meet the study’s predefined criteria for significant excess body weight loss (excess weight loss >20%) when compared to a placebo device.

The strengths of this study include the strict design with regards to the outlined efficacy and safety objectives, as well as the randomization and blinding utilized given the invasive nature of the investigated intervention. Limitations of the study include the small percentage of study participants with type II diabetes. Given the potential for associated confounding factors, it is understandable why the authors decided to limit the number of diabetic participants in the study. However, since a large percentage (>10%) of patients with morbid obesity have type II diabetes, this exclusion hinders the generalization of these results to the population at large. Keeping these limitations in mind, this study suggests that intermittent intra-abdominal vagal nerve block does not produce significantly superior results (>10% difference in weight loss from controls) when compared to placebo therapy.

Click to read the study, published today in JAMA

RELATED REPORTS

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

#VisualAbstract: Once-Weekly Mazdutide Reduced Body Weight in Obese or Overweight Chinese Adults

#VisualAbstract: Tirzepatide Superior to Semaglutide in Obese Adults Without Diabetes

Click to read the accompanying editorial, published today in JAMA

Relevant Reading: Bariatric surgery versus non-surgical treatment for obesity: a systemic review and meta-analysis of randomised controlled trials

In-Depth [randomized controlled trial]: This multicenter study enrolled 239 participants with a body max index (BMI) between 35-45 and at least one co-morbidity related to obesity, and randomized them to receive either an active vagal nerve block device or a placebo device. The primary objectives regarding device efficacy were to 1) assess the mean percent of excess weight loss between the two groups and 2) for 55% of patients in the experimental group to achieve 20% excess weight loss and for 45% to achieve at least 25% excess weight loss. Results showed that the mean percentage of excess weight loss was 24.4% in the active device group and 15.9% in the placebo device group, with a mean difference of 8.5% (95%CI, 3.1-13.9). Fifty-two percent of participants achieved the 20% excess weight loss mark, and only 38% achieved 25% excess weight loss. Consequently, neither of these two primary endpoints for device efficacy was achieved.

The primary objective regarding device safety was to demonstrate an adverse event rate of <15%. This objective was met, with only 3.7% of participants reporting an adverse event related to the device, and 8.6% of participants reporting an adverse event when adverse events related to surgery and anesthesia were included. The most common adverse effects related to the device were nausea, heartburn, and pain at the implantation site.

More from this author: The CLARITY trial: Adding clopidogrel to STEMI management [Classics Series], Aspirin vs warfarin in atherosclerotic intracranial stenosis [Classics Series], The ARISTOTLE trial: Apixaban vs warfarin in atrial fibrillation [Classics Series], The TRITON trial: Prasugrel vs clopidogrel in ACS [Classics Series], Vena caval filters in pulmonary embolism prophylaxis [Classics Series]

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: bariatric surgeryBMIobesity
Previous Post

Low-carb, not low-fat, diet linked with increased weight loss

Next Post

Higher sodium intake linked to more aggressive multiple sclerosis

RelatedReports

Sleep duration inversely related to childhood type 2 diabetes risk makers
Cardiology

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

June 23, 2025
#VisualAbstract: Once-Weekly Mazdutide Reduced Body Weight in Obese or Overweight Chinese Adults
StudyGraphics

#VisualAbstract: Once-Weekly Mazdutide Reduced Body Weight in Obese or Overweight Chinese Adults

June 16, 2025
#VisualAbstract: Tirzepatide Superior to Semaglutide in Obese Adults Without Diabetes
StudyGraphics

#VisualAbstract: Tirzepatide Superior to Semaglutide in Obese Adults Without Diabetes

May 20, 2025
Food environment associated with gestational diabetes
Pharma

Eli Lilly Takes Legal Action Against Telehealth Startups

May 15, 2025
Next Post
Higher sodium intake linked to more aggressive multiple sclerosis

Higher sodium intake linked to more aggressive multiple sclerosis

3D mammography (tomosynthesis) enhances accuracy of breast cancer screening

No mortality benefit with bilateral mastectomy vs breast-conserving surgery

Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]

Beta-blockers ineffective for treating combined heart failure and atrial fibrillation

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.